| HOME >> BIOLOGY >> TECHNOLOGY |
As of December 31, 2007, AMT had cash and cash equivalents of EUR 51.3 million, compared to EUR 14.1 million at December 31, 2006.
Ronald Lorijn, CEO of AMT, said: "AMT had an excellent 2007. We believe we have forged a company that rests on very solid foundations and that is today a leading force in bringing gene therapy to the clinic. The proceeds from our successful initial public offering in June 2007 allow us to continue to execute our business plan, bring our lead product to the clinic, and accelerate the development of our pipeline programs, focused on serious disorders for which there is currently no treatment. We expect to continue to make solid progress in our clinical programs and business development activities, and look forward to update our investors as these materialize."
Conference call and webcast presentation
AMT will conduct a conference call open to the public today at 10.00 CET, which will also be webcast. Netherlands Dial In: 0800-949-4517 (toll free); US Dial In: +1-866-291-4166 (toll free); UK Dial In: +44-207-107-0611. The webcast can be accessed via AMT's website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial In: +41-91-612-4330; +44-20-7108-6233; or +1-866-416-2558; conference ID 14203 followed by #. The archived webcast also will be available for replay shortly after the close of the call.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to
circumvent many if not all of the obstacles that have prevented gene
therapy to become a mainstay of clinical medicine. Using adeno-associated
viral (AAV) vectors as the delivery vehicle of choice for therapeu
'/>"/>
| SOURCE Amsterdam Molecular Therapeutics B.V Copyright©2008 PR Newswire. All rights reserved |